{"entity":{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","aka":[],"tldr":"In a small trial, the antibody-drug conjugate trastuzumab deruxtecan shrank brain metastases in almost three quarters of women with HER2-positive breast cancer, showing that a large antibody-based drug can work inside the brain.","summary":"Single-arm phase 2 trial of 15 patients with HER2-positive breast cancer and newly diagnosed or progressing brain metastases not needing immediate local therapy, treated with trastuzumab deruxtecan 5.4 mg/kg.\n\nIntracranial response by RANO-BM criteria was 73.3 percent in the intention-to-treat population, with a median progression-free survival of 14 months and preserved quality of life. The larger DESTINY-Breast12 study later confirmed intracranial activity in a broader population.","asOf":"2026-09-17","links":[{"label":"Nat Med 2022","url":"https://doi.org/10.1038/s41591-022-01935-8"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35941372/"}],"tags":[],"related":[],"cancers":["her2-positive-breast-brain-metastases"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["tuxedo-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine"],"dependsOn":[],"notes":[],"journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01935-8","pmid":"35941372","authors":"Bartsch R, Berghoff AS, Furtner J, et al.","paperType":"observational","findings":["Intracranial objective response 73.3 percent.","Median progression-free survival 14 months."],"whatItMeans":"Trastuzumab deruxtecan is an option for active HER2-positive brain metastases, complementing tucatinib-based therapy, and challenges the assumption that antibody-drug conjugates cannot reach the brain.","caveats":["Very small single-centre study.","Patients with lesions needing urgent local treatment were excluded."],"changedPractice":true,"participants":15},"route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/","neighbours":{"cancer":[{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"trial":[{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/"}],"journal":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/"}]}}